Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.

The global Heart Failure Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Heart Failure Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Heart Failure Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Heart Failure Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Heart Failure Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm

Segment by Application
Hospital
Clinic
Medical Research Organization